Skip to main navigation
Skip to search
Skip to main content
WashU Research Profiles Home
Help & FAQ
Link opens in a new tab
Search content at WashU Research Profiles
Home
Profiles
Research units
Research output
Indolent lymphomas: current and emerging treatment approaches.
David Maloney
,
Brad S. Kahl
, Martin Dreyling
Section of Medical Oncology
Siteman Cancer Center
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Indolent lymphomas: current and emerging treatment approaches.'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Autologous Stem Cell Transplantation (auto-SCT)
25%
Chemotherapy
75%
Clinical Trials
25%
Consolidation Treatment
25%
Current Treatment
100%
Emerging Treatments
100%
Follicular Lymphoma
75%
Frontline Therapy
25%
Immunochemotherapy
25%
Individual Risk
25%
Indolent Lymphoma
100%
Long-term Maintenance
25%
Maintenance Treatment
25%
Molecular Therapeutics
25%
Monoclonal Antibody
25%
New Therapeutics
25%
Overall Survival
25%
Progression-free Survival
25%
Radioimmunotherapy
25%
Refractory Patients
25%
Relapsed/refractory
25%
Response Rate
25%
Risk Profile
25%
Rituximab
50%
Targeted Agents
25%
Targeted Therapeutics
25%
Targeted Therapy
25%
Therapeutic Development
25%
Treatment Strategy
100%
Treatment-naïve
25%
Medicine and Dentistry
Autologous Stem Cell Transplantation
33%
Chemotherapy
100%
Clinical Trial
33%
Diseases
33%
Emerging Treatment
100%
Follicular Lymphoma
100%
Hope
33%
Immunotherapy
33%
Maintenance Therapy
33%
Monoclonal Antibody
33%
Overall Survival
33%
Progression Free Survival
33%
Radioimmunotherapy
33%
Rituximab
66%
Targeted Therapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy Regimens
100%
Clinical Trial
33%
Diseases
33%
Follicular Lymphoma
100%
Immunotherapy
33%
Monoclonal Antibody
33%
Overall Survival
33%
Progression Free Survival
33%
Rituximab
66%